WASHINGTON, Jan. 29, 2015 /PRNewswire/ -- On the eve of
World Cancer Day 2015, amidst the ongoing cost-of-cancer-care
debate, PACE (Patient Access to Cancer care Excellence), a Lilly
Oncology initiative, is launching the PACE Continuous Innovation
Indicators™ (CII). CII is the first evidence-based, customizable
online tool to review progress against cancer over time—initially
covering 12 cancer types. The purpose of the tool is to inform
public policy reforms and other efforts to accelerate continuous
innovation against cancer.
Experience the interactive Multimedia News Release here:
http://www.multivu.com/players/English/7419451-eli-lilly-oncology-pace/
"We have seen tremendous progress in cancer treatment and care
during the past decades, and continuous innovation, with one
discovery building on another, is responsible for most of it," said
John C. Lechleiter, Ph.D., Chairman,
President, and Chief Executive Officer of Eli Lilly and Company
(NYSE: LLY). "To keep the momentum going, we need policies that
support continuous innovation, but first we need a deeper
understanding of the innovations that have occurred, and where we
need to be."
CII will Initially Focus on 12 Tumor Types
For
the first time, CII will make it possible for policymakers, health
policy experts and patient advocates to visualize progress against
cancer over time, gain a better understanding of how value in
cancer treatment evolves and consider the potential impact of
policy reforms on the speed of innovation. The tool will permit the
user to obtain objective measures of progress against cancer,
initially comparing 12 tumor types, including: breast, colon,
endometrium, kidney, liver, lung, pancreas, prostate, skin
(melanoma), stomach, rectum and testes.
At the heart of CII are thousands of pieces of evidence curated
and coded by trained analysts from authoritative, published
sources—such as clinical trial records and meta-analyses,
observational studies and historical references. The tool, which
provides a layered interface with a range of information, generates
summary graphs from which a user can access supporting evidence and
additional information. In its initial launch period, CII will be
made available to other organizations by request.
CII to Launch at Washington,
D.C. Forum
CII will be unveiled today,
Jan. 29, at a forum, "Scoring
Progress Against Cancer: A New Tool to Track Continuous Innovation,
and Public Policies to Speed It Up," attended by approximately 90
patient advocates, researchers, policy experts and thought leaders.
The forum will feature a panel discussion on policy reforms to
speed continuous innovation against cancer. It will be moderated by
health technology assessment expert Clifford Goodman, Ph.D., PACE Global Council
participant and Senior Vice President and Director, Center for
Comparative Effectiveness Research, The Lewin Group. Distinguished
speakers and panelists include: John C.
Lechleiter, Ph.D., Chairman, President, and Chief
Executive Officer, Eli Lilly and Company; Jeff Allen, Ph.D., Executive Director, Friends
of Cancer Research; Alan Balch,
Ph.D., Chief Executive Officer, National Patient Advocate
Foundation; Peter Huber, Ph.D.,
J.D., Senior Fellow, Manhattan Institute; Lynn M. Matrisian, Ph.D., M.B.A., Vice President
of Scientific and Medical Affairs, Pancreatic Cancer Action
Network; and Silvia Paddock, Ph.D.,
lead CII researcher and Senior Associate, Rose Li and Associates. The forum will be held
from 12:30-2:45 p.m. EST at the
Knight Conference Center at the Newseum in Washington, D.C., and is sponsored by PACE,
Friends of Cancer Research and the National Patient Advocate
Foundation. To view the live stream, register at
https://pacenetworkusa.com/register.php.
CII emerged from a two-year collaboration between PACE and
Rose Li and Associates, a U.S.-based
research firm. A manuscript, "PACE Continuous Innovation
Indicators—A Novel Tool to Measure Progress in Cancer Treatments,"
was accepted for publication in ecancermedicalscience journal on
Jan. 7, 2015. To learn more about
CII, visit www.pacenetworkusa.com/continuousinnovation.
About PACE
PACE, now in its fourth year, is a
global collaboration that encourages public policies and healthcare
decisions that speed the development of new medicines, assure
cancer treatments respond to the needs and qualities of individual
patients and improve patient access to the most effective cancer
medicines. PACE engages key oncology stakeholders, including:
patients, advocacy, payers, policymakers, providers, the public,
researchers and politicians. To learn more about PACE, please visit
https://pacenetworkusa.com/.
About Lilly Oncology
For more than fifty years, Lilly
has been dedicated to delivering life-changing medicines and
support to people living with cancer and those who care for them.
Lilly is determined to build on this heritage and continue making
life better for all those affected by cancer around the world. To
learn more about Lilly's commitment to people with cancer, please
visit http://www.lillyoncology.com/patient/.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
newsroom.lilly.com/social-channels. (C-LLY)
Refer to: (+31) 06-1500-6046; ramers_corina@lilly.com;
Corina Ramers-Verhoeven (Lilly)
(212) 453-2142; m.shin@togorun.com; Madeleine Shin (TogoRun)
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/scoring-progress-against-cancer-new-tool-measures-cancer-progress-to-help-inform-research-and-policy-decisions-300027615.html
SOURCE Eli Lilly and Company